Cargando…
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy
Muscular dystrophy and dilated cardiomyopathy are intractable diseases and their treatment options are very limited. Transient receptor potential cation channel subfamily V, member 2 (TRPV2), is a stretch-sensitive Ca(2+)-permeable channel that causes sustained intracellular Ca(2+) increase in muscu...
Autores principales: | Iwata, Yuko, Matsumura, Tsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720432/ https://www.ncbi.nlm.nih.gov/pubmed/31394715 http://dx.doi.org/10.3390/ijms20163844 |
Ejemplares similares
-
A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy
por: Matsumura, Tsuyoshi, et al.
Publicado: (2017) -
Reply to “The Effects of Tranilast on Cardiomyopathy in Becker Muscular Dystrophy Requires Profound Cardiac and Neurologic Evaluations”
por: Matsumura, Tsuyoshi, et al.
Publicado: (2018) -
Impact of the TRPV2 Inhibitor on Advanced Heart Failure in Patients with Muscular Dystrophy: Exploratory Study of Biomarkers Related to the Efficacy of Tranilast
por: Takahashi, Chisato, et al.
Publicado: (2023) -
The experiences of patients with Duchenne muscular dystrophy in facing and learning about their clinical conditions
por: Fujino, Haruo, et al.
Publicado: (2016) -
Cardiac Dysrhythmias, Cardiomyopathy and Muscular Dystrophy in Patients with Emery-Dreifuss Muscular Dystrophy and Limb-Girdle Muscular Dystrophy Type 1B
por: Hong, Jong-Seo, et al.
Publicado: (2005)